Although the significance of Smad3 protein of TGFβ pathway in ASCVD has been demonstrated in various genetic and knock down studies [15–24], development of non-toxic Smad3 inhibitors have been a challenge due to unknown mechanism and toxicity of inhibitors. Here, SMAD3 is linked to atherosclerosis.